Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa

Table 1

Demographic data, tumor features, and response, in 6 patients with ocular adnexal lymphoma treated with Rituximab immunotherapy.

No.	Age, sex	Eye	Stage	Location	RTX cycles	Interim response	RTX response	RTX maintenance	Survival status	FU months	Final status
1	54/F	OS	IE	C	6	SD	CR	No	Alive	34+	CR
2	62/M	OS	IE	C	6	n.e.	CR	Yes	Alive	27+	CR
3	59/F	OD	IE	C	6	n.e.	CR	Yes	Alive	31+	CR
4	67/F	OS/OD	IE	C	6	n.e.	PR	No	Dead	8	—
5	54/M	OS	IE	O	6	CR	CR	Yes	Alive	31+	CR
6	37/F	OD	IE	O	6	PR	PR	Yes	Alive	9+	PR

M: male; F: female; OS: left eye; OD: right eye; C: conjunctive; O: orbit; SD: stable disease; PR: partial response; CR: complete response; n.e: not evaluated; RTX: rituximab; FU: follow-up.
Lung carcinoma.